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The leucine-rich repeat-containing G protein-coupled receptors (LGRs) family consists of
three groups: types A, B, and C and all contain a large extracellular domain (ECD) made
up of the structural motif – the leucine-rich repeat (LRR). In the LGRs, the ECD binds
the hormone or ligand, usually through the LRRs, that ultimately results in activation and
signaling. Structures are available for the ECD of type A and B LGRs, but not the type C
LGRs. This review discusses the structural features of LRR proteins, and describes the
known structures of the type A and B LGRs and predictions that can be made for the
type C LGRs. The mechanism of activation of the LGRs is discussed with a focus on the
role of the low-density lipoprotein class A (LDLa) module, a unique feature of the type C
LGRs. While the LDLa module is essential for activation of the type C LGRs, the molecular
mechanism for this process is unknown. Experimental data for the potential interactions
of the type C LGR ligands with the LRR domain, the transmembrane domain, and the
LDLa module are summarized.
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Introduction
The receptors for the peptide hormones H2 relaxin and insulin-like peptide-3 (INSL3) are unique
members of the leucine-rich repeat-containingGprotein-coupled receptors (LGRs) family (1). LGRs
are class A G protein-coupled receptors (GPCRs) and are divided into three groups: types A, B, and
C. Type A LGRs are receptors for the glycoprotein hormones follicle-stimulating hormone (FSH),
luteinizing hormone (LH), and thyroid-stimulating hormone (TSH). Although the Type B LGRs
were identified in 1998 (1, 2), LGR4-6 were only recently deorphanized as the R-spondin (Rspo)
receptors (3, 4). These receptors have roles in stem cell differentiation and are associatedwith cancers
affecting the gut. The identification of LGR7 in 2000 resulted in the formation of the third group,
Type C (1). Soon after, LGR7 was joined by the receptor encoded by the GREAT gene (5), (LGR8),
when the phenotype of the knockout mouse correlated with abnormal testicular descent noted in
INSL3 knockout mice (6, 7). In 2002, LGR7 and LGR8 were deorphanized as H2 relaxin receptors
(8). At this exciting time of GPCRdeorphanization, the grouping of LGR7 [later defined as RXFP1 in
Ref. (9)] and LGR8 (RXFP2) with the glycoprotein hormone receptors into the LGR family appeared
to correlate with the known reproductive roles and tissue-specific expression of H2 relaxin and
INSL3. H2 relaxin is a major circulating hormone produced by the corpus luteum and placenta with
important roles inmaintaining pregnancy and facilitating parturition [reviewed in Ref. (10)]. INSL3
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is produced in testicular Leydig cells in males and follicular theca
cells in the female ovary (11), and therefore, has central roles
in fertility.
Almost 15 years since the initial identification of RXFP1, the
landscape of H2 relaxin research is diverse and complex. H2
relaxin is considered a pleiotropic hormone with many func-
tions, including central roles in collagen turnover (12, 13) wound
healing (14), and roles in cardiovascular function (15) [further
reviewed in Ref. (10)]. The key roles of relaxin in cardiovascular
function lead to the use of the human form of relaxin, H2 relaxin,
in clinical trials for the treatment of acute heart failure. With the
success of these clinical trials (16–18), a clear understanding of
the mechanism of how H2 relaxin binds and activates RXFP1 is
highly desirable. Unfortunately, no structures of a Type C LGR
are available. In this context, as structural understanding of other
members of the LGR family grows, we review the structural
knowledge of the LGR family, and examine what is known about
ligand interactions at the extracellular domains (ECDs) of the
Class C LGRs in comparison to the other members of this diverse
family of GPCRs.
Leucine-Rich Repeat-Containing G-Protein
Receptor
The LGR family is classified as “Type A” rhodopsin-like GPCRs
based on the similarity of its transmembrane (TM) domain. They
are unified into this family based on their large ECDs containing
leucine-rich repeats (LRRs). The first LRR-containing protein to
be identified was leucine-rich α2-glycoprotein (LRG) (19) but
since then, LRR domains have been identified in various pro-
teins including extracellular, intracellular, and TM proteins with
a wide variety of functions, such as neural circuit formation
[reviewed in Ref. (20)], inflammation [reviewed in Ref. (21)],
immune response against pathogen (22, 23), and development and
immunity in plants (24).
LGRs Classification
The LGR family is differentiated on the basis of the number of
LRRs within the ECD, the length of the hinge region between
the LRR domain and the TM domain and the presence of a
low-density lipoprotein class A (LDLa) module (25, 26). Cur-
rently, there are three types of LGRs: type A, type B, and type
C (Table 1). Mammalian type A LGRs include the follicle-
stimulating hormone receptor (FSHr), thyroid-stimulating hor-
mone receptor (TSHr), and luteinizing hormone receptor (LHr)
[or lutropin/choriogonadotropic receptor (LCGr)] (27). Type A
are characterized by 7–9 LRRs within the LRR domain and have
a distinctively long hinge region, connecting the LRR to the
TM domain, which is essential for receptor activation (26). The
type B LGRs (LGR4–6) are the receptors for the Rspo family
(R-spondin1–4) and have roles in development, including cell
proliferation and differentiation, and oncogenesis (28). These
LGRs, typically have 16–18 LRRs and so constitute a longer
LRR domain than type A and type C LGRs (26). The hinge
region of type B LGRs is “medium length” compared to that
of type A. Type C members are distinct in that they have an
N-terminal LDLa module, which is also known to be impor-
tant for receptor activation (29). These latter receptors include
the mammalian LGR7 and LGR8 (now known as RXFP1 and
RXFP2, respectively) along with a snail LGR and LGR3 and LGR4
from Drosophila (30) and are grouped as C1 or C2 based on
the number of LDLa modules in their ECD. Type C LGRs have
a similar number of LRRs compared to type A LGRs, although
they have a shorter hinge region connecting the LRR domain
to the TM domain (26). There is no evidence to suggest that
the hinge has the same role in modulating receptor activity
as it does in type A LGRs. RXFP1 and RXFP2 are the only
mammalian class C LGRs and contain a single LDLa module,
while type C LGRs found in echinoderm and molluskan can
contain up to 12 modules (26). Thus, the evolution of these
receptors is difficult to determine and in the context of this
TABLE 1 | Ectodomains and ligands of the LGR family.
Name Short annotated
name
Ligand No of
LRRs
Residues per
repeat
Ligand affinitya PDB
Type A
LGR1 FSHr Follicle-stimulating hormone 9 21–25 0.03–3 nMb 1XWD, 4AY9, 4MQW
LGR2 LH/CGr Lutropin or choriogonadotropic hormone 6 22–31 0.3–0.5 nMc
LGR3 TSHr Thyrotropin (thyroid-stimulating hormone) 7 20–31 0.25 nMd 3XWT,3GO4
Type B
LGR4 LGR4 Rspondin1–4 17 20–25 56 nMe 4KT1, 4QXE, 4QXF
LGR5 LGR5 Rspondin1–4 17 21–26 3 nMf 4BSR, 4BSS, 4BST
4BSU, 4KNG
LGR6 LGR6 Rspondin1–4 17 21–25 0.5–7 nMg
Type C
LGR7 RXFP1 H2 relaxin 10 24–25 9.2–9.8h 2JM4 (LDLa module)
LGR8 RXFP2 INSL3, H2 relaxin 10 24 9.3–9.7, 8.5–9.0h 2M96 (LDLa module)
aReported Kd, unless noted.
bSimoni et al. (31).
cAscoli et al. (32).
dHarfst et al. (33).
eWang et al. (34).
fde Lau et al. (3).
g IC50 (35).
hpKd or pKi (36).
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review only the mammalian RXFP1 and RXFP2 receptors will be
discussed.
Structural Features of LRR Domains
The LRR Domain
The first structure of a LRR-containing protein, ribonuclease
inhibitor (RI), showed a horseshoe-shaped structure (37). This
curved structure consists of a β-sheet on the concave side of
the LRR and an array of α-helices on the convex side. A single
LRR consists of a β-strand and α-helix connected with loops and
therefore a sequence of LRRs forms alternating parallel β-strands
and α-helices along the α/β fold (38). The β-strand is formed by a
highly conserved motif, xLx, within a LRR, connected to adjacent
parallel β-strands by hydrogen bonds to form the β-sheet on the
concave side of the structure. Comparison of LRR domains show
the presence of a repeated conserved hydrophobic-rich sequence
motif, LxxLxLxxNxL, where the underlined residues form the β-
strand, x is any amino acid and leucine may be substituted by
valine, isoleucine or phenylalanine; and asparagine by cysteine,
serine or threonine (38, 39).
The convex side of the LRR domain is comprised of more
variable sequence and secondary structure including 310 helices,
polyproline II helices, β-turn or β-strand (39). In addition to the
length, the nature of the sequence contributes to the curvature
of the LRR domain. Two distinct sequences are observed on the
convex side, LPxxL (LP motif) and IxxxAF (AF motif) (40). The
prototype LRR protein comprising the LP motif is the platelet-
receptor glycoprotein Ibα that has a steep curvature (41), whereas
the prototype AFmotif is the Nogo receptor which has a relatively
flat curvature (42). The LRR domain is an exceptionally stable
solenoid-like structure. The side chains of the leucine residues (or
other aliphatic residues) are closely packed and oriented toward
the interior of the domain to form a hydrophobic core in a
similar fashion as observed in other globular proteins (39). The
β-sheet along its concave side also contributes to the stability of
the structure as each β-strand forms five hydrogen bonds to the
adjacent β-strand. To further stabilize the structure, the conserved
asparagine residues (on the concave side) form an asparagine
ladder where the side chains stack on top of adjacent asparagine
residues and form hydrogen bonds (39, 43). For LRR proteins
with repeating AF motifs, the phenylalanines on the convex side
form a phenylalanine spine that also adds to the stability of the
LRR domain (42, 44). Commonly, a binding site is located in the
concave surface of the LRR domain, however, the convex surface
also can be utilized as site of ligand interaction (39).
The N- and C-Terminal Caps
Although the LRR domain is a stable solenoid structure, it would
appear that capping structures are essential to maintain stabil-
ity. In most cases, especially extracellular LRR and membrane-
associated LRR proteins, there are cysteine-rich subdomains at the
N- and C-terminal ends of the LRR domain, termed N-terminal
(LRRNT) and C-terminal (LRRCT) capping motifs, respectively.
Based on sequence analysis, LRRNT motifs have a consensus
sequence of CPx(2-5)CxCx(6-19)Cx(6-8)Px(3)Px(5)LxL, where x
indicates any residue (39, 45). The typical structure of LRRNT
contains a β-strand antiparallel to themain LRR β-sheet, followed
by 20 to 21 residues before entering a β-strand that is parallel to
the LRR. As this strand is often not a canonical LRR, it is excluded
from the description of the body of the LRR domain.
Based on phylogenetic analysis and the number of cysteine
residues present, there are four types of LRRCT motifs, CF1–4
(45). CF1 is the most common capping structure containing four
cysteines (CxCx(17–24)Cx(9–18)CxxP). CF2 has two cysteines,
separated by 33 to 34 residues and is found in small proteoglycans,
CF3 has three cysteines (CCx(14–27)C) found inGPCRs, andCF4
has two cysteines separated by 1 to 11 residues and is found in
plant LRR proteins.
Structures of LGRs
Type A LGRs
The FSHr crystal structure is the best understood of the LGRs
(46). The LRR domain consists of repeats of irregular length
and conformation (Figure 1A). As expected the LRR domain
contains an LRRNT with an antiparallel β-strand followed by
the expected parallel β-strand of this cap. This is then followed
by nine parallel β-strands of the LRR domain (Table 1), and
additional two parallel β-strands in the C-terminal cysteine cap,
which form a typical CF3 cap. Prior to the last parallel β-strand,
there is an insertion of an α-helix and a long hairpin loop that
contains a sulfated tyrosine, collectively referred to as the hinge
region, and forms an integrated structure within the LRR domain
(Figure 1A) (47). Consequently, the entire LRR domain consists
of 12 parallel β-strands. On the convex side of the LRR domain,
there are seven short β-strands separated into three β-sheets.
Importantly, the intervening sequences of the convex side follow
from the N-terminal end as: an LP motif, three AF motifs, one
LP motif, two AF motifs, and then three LP motifs. Thus, there
is an increasing curvature of the domain running from N- to C-
terminus. Superimposing the structures of the FSHr and TSHr
LRR domains shows similar structures despite different primary
sequences and disulfide connectivity (40).
Upon binding to ligand, there is a significant change to the
hinge structure of FSHr, otherwise the LRR domain is similar to
that of the ligand free (47). The binding of FSH is described as
a “handclasp” interaction, where 10 parallel β-strands of FSHr,
including the parallel β-strand of the LRRNT, are in contact with
the hormone mainly via electrostatic interaction (46). The inter-
actions can be divided into two flat surfaces; one is where the C-
terminal end of theα- and β-units of FSH interactwith the parallel
β-strand of the LRRNT and the first six LRRs and the other is
where the second loops of the α- and β-units of FSH interact
with the tips of the β-strands of LRR1–5 and the C-terminal
ends of LRR7–9, respectively. The hairpin loop between the
last two parallel β-strands presents an essential tyrosine residue,
which becomes sulfated (sTyr). This sTyr makes an important
contribution to ligand binding by inserting into a hydrophobic
pocket in FSH. As it is clear that FSH can bind in the absence
of this hinge region, this structure provides evidence of a “two-
step” binding mechanism (47). Following FSH binding to FSHr,
the sTyr binds to the hormone lifting the hairpin loop from an
inhibitory state of the TM domain that results in activation of
the receptor.
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FIGURE 1 | Structures of ectodomains of members of the LGR family.
(A) The type A member FSHr (PBD: 4AY9) shows nine LRRs. LRR1–6 show a
shallow curvature while the dominance of LP motifs in the convex side of
LRR7–9 results in a steep curvature. The ligand shows interactions to most of
the LRRs, especially LRR1–5 and LRR7–9 (B) The type B member LGR4 (PDB:
4KT1). The concave side of the LRR protein is separated into two sheets,
LRR1–10 and LRR11–17, due to the absence of the conserved Asn residues
within the LRR motif of LRR11 and 12. The ligand binds to the first sheet,
making contacts with residues in LRR1, LRR3–9. (C) A homology model of the
ECD of the type C member RXFP1. The 10 LRRs are predicted to form a
shallow curvature. The ligand, H2 relaxin, is expected to bind to LRR4–6 and
LRR8. The structure of the N-terminal LDLa module (PDB: 2JM4) for this ECD is
also shown, although the structure of the linker that joins to the LRR domain
remains unknown. In each structure, additional β-strands (red), which are
integral to the domain, are shown but these strands typically lack the xLx
portion of the LRR motif, and usually include disulfide bonds characteristic of
the N- and C-terminal capping motifs. At the N-terminal end of each LRR
domain, an antiparallel β-strand followed by a β-strand parallel to the remainder
of the LRR is observed. At the C-terminal end, significant differences for the
three members are observed. For FSHr, a large hinge containing a functionally
important sulfated Tyr residue is present; for LGR4, this hinge is absent, but a
typical CF3 capping motif is present; for RXFP1, the C-terminal cap does not
appear conserved, the hinge is short, and therefore, the structure of this region
is difficult to predict.
The LRR domain and the ligand of FSHr and TSHr are similar,
although the disulfide arrangement of the LRRNT differs (48).
Nevertheless the mechanism is suggested to be the same for these
receptors as TSHr has a structurally similar sTyr site (49, 50),
which is essential for TSH binding and activation (51–53). Cur-
rently, there is limited knowledge about the activationmechanism
of LHr. Although the sTyr site is present in the hinge region of LHr
(54, 55), the mechanism of LHr differs from FSHr and TSHr as
removal of the ectodomain does not result in constitutively active
receptor (56).
Type B LGRs
The LRR domains in Type B LGRs are typically larger than those
of Type A LGRs (Table 1). The crystal structures of both LGR4
and LGR5 comprise 17 typical LRR β-strands with an N-terminal
antiparallel β-strand followed by another β-strand that is parallel
to the LRR domain, and two additional parallel β-strands at
the C-terminus (Figure 1B) (34, 57). On the convex side, the
secondary structures are more variable with various lengths of
loops,α-helices, and β-strands. In LGR4 andLGR5, the conserved
asparagine residues in LRR11 and LRR12 are missing, resulting
in two separate β-sheets, one from LRR1–10 and the other from
LRR13–17 (Figure 1B) (34, 58–60). The intervening sequences
on the convex side follow from the N-terminal end: in the first
β-sheet, two AF, four LP, one AF, two LP, and one AF; and in the
second β-sheet, three LP, two AF, and one LP motif. The large
number of LPmotifs result in a more curved surface than the type
A receptors. These proteins have a typical LRRNT, whereas the
LRRCT has a short four-residue intervening sequence within the
otherwise CF3 cap.
Recently, Rspos were identified as the native ligands of type
B LGRs (4, 61, 62). In LGR4, the ligand binds to the first LRR
and LRR3–LRR9 (the first β-sheet) and the binding interface is
smaller compared to FSH–FSHr (1860 compared to 2600 Å2)
(34, 60). The interface is mainly electrostatic within LRR4 and
hydrophobic within LRR5–7. Similar to LGR4, the LGR5 binding
interface consists of LRR3–9 with total surface area of 870Å2
(58). LGR5 binds to Rspo in a similar manner to LGR4, a mix of
charged and hydrophobic clamping interactions. Based on these
observations, the binding of Rspo is conserved across the type B
LGRs and it is supported by the fact that there is lack of specificity
between different Rspos and type B LGRs (3). In type B LGRs,
there is no evidence that the hinge region or even the LRRCT is
involved in ligand binding or activation. The LRRCT of LGR4
can be deleted or substituted with LRRCT motifs from other
proteins without affecting activity or binding (63). Moreover,
antibodies targeted to the LRRCT of LGR5 do not block Rspo
activity (62). However, another antibody targeted specifically to
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the hinge region has been shown to induce activity in the absence
of Rspo (58).
While there are similarities in how typeA and type B LGRs bind
ligand, the signal pathways and receptor activation are different.
Rspo signalingmediated by LGR4, LGR5, or LGR6 is throughWnt
signaling and not the canonical GPCR pathways (3, 61, 63), which
is in contrast to type A and type C LGRs. Multiple mechanisms
have been proposed to explain how type B LGRs regulateWnt sig-
naling. The binding of Rspo to the ectodomains of LG4–6 recruits
the E3 ligases (RNF4 and ZNRF3) to form a ternary complex that
promotes clearance of the E3 ligase, thus a reduction inWnt recep-
tor ubiquitination and degradation, and consequently increased
Wnt signaling (64). In addition, the Rspo–LGR4 recruits the
scaffold protein IQ motif containing GTPase-activating protein 1
(IQGAP1) into the Wnt complex to potentiate signaling (65).
Type C LGRs
Presently, there are no structures of the LRR domains of type C
LGRs. However, the structures of type A and type B LGRs, as
well as those of other LRR domains, allow predictions to be made
for this class of LGRs. Based on the primary sequence, the LRR
domain is expected to have 10 LRR repeats (Table 1) with an N-
terminal antiparallel β-strand and an additional parallel β-strand
forming the N-terminal cap. Analysis of the LRRs from the type C
LGRs, RXFP1 andRXFP2, suggests that the LRRs aremore regular
than the type A and type B LGRs. The intervening sequences on
the convex side of RXFP1 following from the N-terminal end
are predicted to be four AF, one LP, two AF, and one LP motif.
Such an arrangement predicts a relatively flat surface and the
predominance of the AF motif allows straight forward homology
modeling of the LRR domain of RXFP1 based on the prototypeAF
motif Nogo receptor (42). A homology model built by Modeler
(66), using the Nogo receptor (PDB: 1OZN) as a template with
~29% sequence identity, shows a spine of phenylalanine residues
down the convex side, except at LRR5 where a leucine residue is
aligned, and a ladder of asparagine residues of the LRR motif on
the concave side of themodel (Figure 1C). The conservation of the
N-terminal cysteine residues predicts an LRRNT similar to type A
and type B LGRs. However, there are only two cysteine residues in
the C-terminal hinge of RXFP1, separated by eight residues, and
therefore are CF4-like rather than the CF3 cappingmotif expected
in LRR-containingGPCRs (45). Thereforemodeling of this region
against the Nogo receptor, or any other LRR protein, is highly
speculative. The hinge region of RXFP1 and RXFP2 is relatively
short (~30 residues compared to 72–123 residues in other LGRs)
(1). Considering the shortness of the hinge region and the fact that
the LDLa module at the N-terminus is key for receptor activation
suggests that the hinge region in the RXFPs might not be involved
in the binding and activation mechanism of these receptors.
The cognate ligands of RXFP1 and RXFP2 are H2 relaxin and
INSL3, respectively. These peptides share structural similarity to
insulin, where an A-chain and a B-chain are held together by two
disulfide bonds (67, 68). Extensive studies of these two peptides
conclude that the B-chain is essential for receptor binding [as
reviewed in Ref. (10)]. The B-chain binding cassette of H2 relaxin
is defined as RxxxRxxI/L, where x is any amino acid, and of INSL3
as HxxxRxxVR (68). Furthermore, a tryptophan residue located
at the C-terminal of the B-chain is wrapped back around the
structure of INSL3 and has been shown to be essential for binding
and activation of its receptor, RXFP2 (69, 70). Binding to the
LRR domains of RXFP1 and RXFP2 has been extensively studied
by mutagenesis of both the receptors and H2 relaxin or INSL3.
Previous modeling of the H2 relaxin–RXFP1 interaction has used
RI as a template and subsequently, mutagenesis studies were per-
formed to verify thismodel (71). Themodel of H2 relaxin–RXFP1
shows the conserved basic residues (Arg13 and Arg17) in the B-
chain interact with acidic residues within the LRR6 and LRR8 of
RXFP1, respectively. The other conserved hydrophobic residue
(Ile20) within the B-chain is predicted to interact with a cluster
of hydrophobic residues across LRR4-5. Hence, based on these
data, it is proposed that H2 relaxin binds to the LRR domain
at a 45o angle across the face of LRR4–8. Scott et al. (72) also
used the Nogo receptor as a template to model the INSL3–RXFP2
interaction, and given the expected structural similarity of RXFP1
and RXFP2 with the Nogo structure we present a model of RXFP1
(Figure 1C). The model of INSL3–RXFP2 concludes that the
positively charged residues (Arg16 and Arg20) of INSL3 interact
with negatively charged residues in LRR6 and 8 and the conserved
hydrophobic residues in the B-chain of INSL3 (His12, Val19, and
Trp27) with hydrophobic residues across LRR1–4. In this model,
the B-chain of INSL3 requires a larger surface area thanH2 relaxin
and lies perpendicular to the LRRs.
The molecular details of how H2 relaxin and INSL3 bind and
activate RXFP1 and RXFP2 are still ambiguous, despite extensive
research. It is clear that a ligand-binding site is present in the
LRR domain, but the relatively short LRRCT makes it unlikely
to interact with the ligand in a type A LGR manner. While
various receptor constructs show that neither the LDLa module
nor the TM domain are required for high-affinity binding (29,
73), additional weak affinity binding sites for the ligand have been
proposed for both RXFP1 andRXFP2 on the TMdomain (73–75).
Support for an interaction between the ligand and the TMdomain
includes experiments conducted on human relaxin 3 (H3 relaxin)
(76), a homolog ofH2 relaxin, and INSL3.H3 relaxin binds to both
RXFP1 and RXFP3 (GPCR135). The latter lacks an ECD and so
binding and activation is solely through the TMdomain of RXFP3
(77). Taking advantage of the binding specificity of H3 relaxin for
RXFP1 over RXFP2, ECD/TMdomain chimeras of RXFP1/2 were
constructed and tested for ligand binding and signaling (74). The
chimera of the ECD of RXFP1 with the TM of RXFP2 binds H3
relaxin more weakly than to wild-type RXFP1, and signaling is
reduced. On replacing the exoloop-2 of the TM domain in this
construct with exoloop-2 of RXFP1, binding was similar to wild-
type RXFP1 and signaling was fully restored, supporting an inter-
action by H3 relaxin with both the ECD and exoloop-2 of RXFP1.
To further investigate the binding of H2 relaxin to the exoloops,
exoloop-1 and exoloop-2 were engineered onto a soluble protein
scaffold preserving the disulfide between exoloop-1 and -2 and
therefore potentially creating a native-like structure of exoloop-
2 (75). Using NMR spectroscopy and pull-down assays, specific
interactions of H2 relaxin were observed to this scaffold, but not
in a construct lacking the disulfide. These latter experiments show
that the ligand binds to the exoloop-2, and also the importance
of the integrity of the conformation of exoloop-2. Furthermore,
Frontiers in Endocrinology | www.frontiersin.org September 2015 | Volume 6 | Article 1375
Petrie et al. Structure and mechanism of RXFP1-2
mutation of a phenylalanine residue (equivalent to Phe564) to
alanine within exoloop-2 showed loss of binding to H2 relaxin,
and when this mutation was tested in the full-length receptor
signaling was lost. Collectively, these data indicate that for type C
LGRs, in contrast to type A and possibly type B, the ligands have
binding sites on both the ECD and TM domain, where the latter
are also essential for activation.
H2 relaxin binds to both RXFP1 and RXFP2, whereas INSL3
only binds RXFP2. To investigate if important differences lie
within the LRR domain or involve the TM domain, a series of
RXFP1/2 chimeras were prepared (78). These included constructs
that swapped the TM domains or consisted of only the ECDs
attached to single TM helices: referred to as 7BP or ECD-1 for
the protein containing the ECD of RXFP1, and 8BP or ECD-2
for RXFP2 (8, 78). To test the contribution of the LRRs within
the ECDs to ligand specificity and activation, residues within the
LRRs of the RXFP1 constructs were swapped with LRRs of RXFP2
in order to gain INSL3 binding. Notably, in contrast to RXFP1,
7BP (ECD-1) binds INSL3, albeitmoreweakly than 8BP or RXFP2
but suggests that a binding site for INSL3 already exists in RXFP1.
A high-affinity binding site for INSL3 was engineered into 7BP
with as little as swapping a single LRR (specifically LRR1), and this
binding was indistinguishable to that for 8BP or RXFP2. However,
when themutations that produce a high-affinity binding of INSL3
in 7BP were tested in full-length RXFP1, no gain in the binding of
INSL3 was observed. As additional binding sites for INSL3 and
H2 relaxin are proposed to be present on the TM domain (73–
75), the TM domain of RXFP2 was also replaced on the RXFP1
construct that included the putative high-affinity binding site for
INSL3. However, again binding or activation by INSL3 was not
recovered. These data suggest thatwhile clearly the LRRdomain of
these receptors harbors a ligand-binding site, additional binding
features remain to be elucidated. Indeed, issues of the juxtapo-
sition of the LRR with respect to the TM domain may sterically
hinder INSL3 binding (78).
There is additional evidence of distinct differences in the mode
of peptide binding to the RXFP1 and RXFP2 ECDs and the
impact on receptor activation. Studies on synthetic H2 relaxin
and INSL3 peptides with A-chain truncations or substitutions
show distinct differences in the ability of the peptides to bind and
activate RXFP1 and RXFP2. H2 relaxin peptides with truncations
of the A-chain (79) or A-chain substitutions with other relaxin
family peptide A chains (80) show loss of binding affinity in both
RXFP1 and RXFP2 with parallel decreases in activation whereas
truncations or alterations in the A-chain of INSL3 do not affect
the high-affinity binding to RXFP2 (81–83) but abolish activa-
tion. These observations highlight that differences in the mode of
ligand binding to these receptors exist and these modes have not
been fully elucidated. Additionally, they highlight that H2 relaxin
binds to RXFP2 in a manner different from the INSL3 mode and
similar to the mode it binds to RXFP1.
The LDLa Module of Type C LGRs
The presence of a unique N-terminal LDLa module distinguishes
RXFP1 and RXFP2 from other LGRs, and indeed are the only
GPCRs to contain this module (84). The LDLa module was first
described as repeating units in the LDL receptor (85) and other
related proteins (86) where they are involved in lipid metabolism.
LDLa modules have since been described in a variety of proteins
both as repeats and single domains in proteins with diverse func-
tions, such as viral entry (87), breast cancer invasion and metas-
tasis (88), and cell differentiation (89). LDLa modules are typi-
cally 4 kDa in size and have highly conserved structural features,
including three disulfide bonds and an essential calcium ligation
motif that contributes to maintaining overall fold and structure of
the modules (85, 90, 91). The significance of the LDLa module in
RXFP1 and RXFP2 was discovered during the characterization of
splice variants of the receptors that lacked the LDLamodules (29).
A naturally occurring splice variant of RXFP2 (LGR8-short) was
identified and found to lack the LDLamodule. While LGR8-short
binds H2 relaxin and INSL3, no INSL3- or H2 relaxin-induced
cAMP signaling was detected. This prompted the production of
an engineered RXFP1 without the LDLa module (LGR7-short or
RXFP1-short) and while it bound H2 relaxin equal to full-length
RXFP1, no cAMP-induced signaling was detected (29). Recently,
a panel of reporter genes was used to assess whether RXFP1 or
RXFP2without the LDLamodule could signal through alternative
GPCR signaling pathways other than those that signal through
cAMP (92, 93). However, both RXFP1-short and RXFP2-short
were unable to signal through any signaling pathway.
The structures of both the RXFP1 and RXFP2 LDLa modules
have been solved using nuclear magnetic resonance (NMR) spec-
troscopy in an effort to understand the importance of specific
residues (84, 93). While RXFP1 and RXFP2 have evolved to use
the LDLa module for an essential role in signal activation, the
molecular details are different between the two receptors. For
example, chimeric RXPF2 (RXFP2–LB2), where the LDLamodule
is replaced with the second ligand-binding domain (LB2) of the
low-density lipoprotein receptor (LDLr), showed some INSL3-
induced cAMPactivity (93), whereas a similar construct of RXFP1
(RXFP1–LB2) showed no significant H2 relaxin-induced cAMP
activity (92). Adding back regions of the native RXFP2 LDLa
sequence into RXFP2–LB2 did increase signaling of the mod-
ule; however, this appeared to be due to reconstitution of the
correct structure rather than specific side chain interactions. In
comparison, in an attempt to rescue signaling in a RXFP1–LB2
chimera, the hydrophobic portions of the side chains of a cluster of
residues (Leu7, Tyr9, and Lys17) were pinpointed to be essential,
highlighting these residues may be involved in receptor activation
(92). The capacity of these chimeric studies are insufficient to
understand exactly the activation mechanism by the LDLa mod-
ule, however, in a separate study using an engineered scaffold
containing the extracellular loops of RXFP1, a weak interaction of
the scaffold with the LDLa module was observed supporting the
notion that it interacts with the TM domain for activation (75).
Thus, in RXFP1 and RXFP2, the LDLa module is not involved in
ligand binding, rather plays a crucial role in receptor activation by
potentially interacting with the TM domain (29, 84, 92, 93). The
LDLa module may therefore act as a tethered ligand that requires
binding of H2 relaxin to mediate activation of the receptor; a
mechanism which is distinct from the Type A LGRs two-step
binding mechanism (47).
Joining the LDLa module to the LRR domain is a linker of
variable length, 32 or 25 residues in human RXFP1 and RXFP2,
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respectively. This linker has been considered a simple tether with
the function of intramolecular localization of the LDLa module
to the TM domain for efficient activation. Swapping the LDLa
module of RXFP2 onto RXFP1 resulted in loss of signaling, sug-
gesting that the LDLa modules cannot be swapped; although in
this study a large portion of the linker of RXFP2 was also swapped
(94). However, in a second study, the LDLamodules of RXFP1 and
RXFP2 were swapped, taking care not to alter the linker length
or sequence, and these showed ligand-mediated activation (95).
In this latter work, swapping the LDLa module of RXFP2 onto
RXFP1, thus preserving the linker, LRR, and TM domains of
RXFP1, showed wild-type H2 relaxin-induced cAMP activation.
Importantly, maximum activation could not be obtained, suggest-
ing that the LDLa module of RXFP2 could not make essential
interactions with the TM domain of RXFP1 for full activation.
These observations are consistent with site-directed mutagenesis
experiments of the LDLa module in full-length RXFP1 (84, 92).
When both the LDLa module and TM domain of RXFP2 were
swapped onto RXFP1,maximum activationwas achieved suggest-
ing that the LDLa module was now acting as a full agonist and the
interactions between the LDLamodule and TMdomainwere fully
restored. Swapping the LDLamodule of RXFP1 onto RXFP2, thus
preserving the linker, LRR, and TM domains of RXFP2, showed
similar potency for both ligands (95). This may reflect the fact
that H2 relaxin is a ligand of both RXFP1 and RXFP2 and the
RXFP2–INSL3 evolvedmore recently (96). Thus the RXFP1 LDLa
module may be equally efficacious on both RXFP1 and RXFP2.
These results are in contrast to the LDLa-linker deletion where
activation was lost (94) and challenge the notion that the linker
is only a tether. Furthermore, these data suggest that the linker
may play a role in activation akin to the hinge of the type A
receptors. Importantly, a natural splice variant of RXFP1 where
the LDLa module and the following linker residues are expressed
as a soluble protein can antagonize the activity of H2 relaxin at
RXFP1 supporting a functional role of the linker (29). Further
research into whether the linker interacts with H2 relaxin or the
TM domain is required.
Conclusion
The LGR family has in common a LRR domain that serves as a
ligand-binding site. From the point of view of mechanism, this is
the only common feature of the three subtypes of receptors. At
the extreme, the type B LGRs on binding ligand do not function
through a canonical GPCR pathway by activation of either G-
proteins or β-arrestin. When the ligand binds to type A LGRs,
it undergoes a conformational change that enables an interac-
tion between the ligand with the C-terminal hinge of the ECD,
which is proposed to release the TM domain of the receptor
from an inhibited state. Evidence presented for the type C LGRs,
RXFP1 and RXFP2, shows that the true agonist of these recep-
tors is the N-terminal LDLa module. Thus, it is hypothesized
for these receptors that the binding of ligand results in a con-
formational change to the ECD to present the LDLa module to
the TM domain for activation. Structures of the ECDs of type
A and type B LGRs, free and in complex with ligand, suggest
that conformational change of the LRR domain of the type C
LGRs is unlikely. Given the size and structure of the ligands,
H2 relaxin and INSL3, and the LDLa modules, it is difficult to
envisage significant conformational changes to these molecules.
Therefore, hypotheses of reorientation of the LDLa module or
localization through modification of the structure of the linker
that tethers the LDLa module to the LRR domain may be key
to the activation process. Further research, including structure
elucidation, is required to understand how the type C LGRs
are activated.
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